Form 4: Conduit Pharmaceuticals Director Acquires Shares in Lieu of Cash Retainer

Director Freda Lewis-Hall acquired 47,612 shares of Conduit Pharmaceuticals in lieu of a cash retainer, while also reporting indirect ownership of additional shares.

Summary

• On March 30, 2025, Freda Lewis-Hall, a director of Conduit Pharmaceuticals, acquired 47,612 shares of common stock at a price of $0.89 per share.
• These shares were issued under the 2023 Stock Incentive Plan in place of $42,375 in accrued cash retainers.
• Following the transaction, Ms. Lewis-Hall directly owns 51,991 shares.
• Ms. Lewis-Hall also reported indirect ownership of 20,033 shares held by Intelmed LLC, where she is the Managing Director, and 5,169 shares held by her spouse, Mr. Emerson Hall, Jr.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a transaction. The director taking shares instead of cash could be seen as slightly positive, but it's not a major event.

Positives

• A director's decision to take shares in lieu of cash may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders if it signals confidence from a director.

Key Dates

Keywords

Conduit Pharmaceuticals, Director, Freda Lewis-Hall, Stock Acquisition, Beneficial Ownership, SEC Form 4, CDT, Intelmed LLC, Stock Incentive Plan